Atrial Fibrillation Medication Study Now Enrolling
Updated: This study is now complete.
September 16, 2015
A research study is currently enrolling patients who have paroxysmal atrial fibrillation (afib that comes and goes). This clinical research study, sponsored by Bristol-Myers Squibb, will evaluate the effectiveness and how well the body tolerates an experimental drug (BMS-919373).
The study will compare the safety and effectiveness of this experimental medication to a placebo (an inactive substance) in determining how well it reduces the amount of time your heart is in atrial fibrillation. Those who are eligible to enroll in this 87 day study will be randomly divided into 4 different groups. Three groups will receive the study medication at different doses, and the fourth group will receive a placebo. Study procedures will be conducted on an outpatient basis at sites in the United States and Canada.
To be eligible, your heart will need to be in afib a certain amount of time. The study doctor will run a noninvasive test, at no cost to you, to determine if you are eligible to participate. If you qualify, you will discontinue your current antiarrhythmic medication in order to evaluate the safety and effectiveness of this experimental medication, or the placebo, throughout your participation in the study.